Azilsartan: Difference between revisions
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
[[File:Azilsartan.svg|Azilsartan|thumb]] | |||
[[File:Azilsartan medoxomil.svg|Azilsartan medoxomil|thumb]] | |||
{{intro}} | {{intro}} | ||
Azilsartan is an angiotensin II receptor blocker (ARB) used in the therapy of hypertension. | Azilsartan is an angiotensin II receptor blocker (ARB) used in the therapy of hypertension. | ||
{{livtox}} | {{livtox}} | ||
It is associated with a low rate of transient serum aminotransferase elevations, but has yet to be linked to instances of acute liver injury. | It is associated with a low rate of transient serum aminotransferase elevations, but has yet to be linked to instances of acute liver injury. | ||
{{moa}} | {{moa}} | ||
Azilsartan (ay" sil sar' tan) is an ARB used alone or in combination with other agents for therapy of hypertension. Azilsartan inhibits the renin-angiotensin system by blocking the angiotensin II type 1 receptor (AT1), which prevents the vasoconstriction and volume expansion induced by circulating angiotensin II and which accounts for its antihypertensive activity. | Azilsartan (ay" sil sar' tan) is an ARB used alone or in combination with other agents for therapy of hypertension. Azilsartan inhibits the renin-angiotensin system by blocking the angiotensin II type 1 receptor (AT1), which prevents the vasoconstriction and volume expansion induced by circulating angiotensin II and which accounts for its antihypertensive activity. | ||
{{fda}} | {{fda}} | ||
Azilsartan was approved for use in the United States in 2011 (the eighth ARB approved for hypertension). | Azilsartan was approved for use in the United States in 2011 (the eighth ARB approved for hypertension). | ||
{{use}} | {{use}} | ||
Current indications are for treatment of hypertension, either alone or in combination with other antihypertensive agents. | Current indications are for treatment of hypertension, either alone or in combination with other antihypertensive agents. | ||
{{dose}} | {{dose}} | ||
Azilsartan is available in 40 and 80 mg tablets under the trade name Edarbi. Fixed combinations of azilsartan (40 mg) with chlorthalidone (12.5 or 25 mg) are also available under the brand name Edarbyclor. The typical dose in adults in 40 to 80 mg once daily, and it is used long term. | Azilsartan is available in 40 and 80 mg tablets under the trade name Edarbi. Fixed combinations of azilsartan (40 mg) with chlorthalidone (12.5 or 25 mg) are also available under the brand name Edarbyclor. The typical dose in adults in 40 to 80 mg once daily, and it is used long term. | ||
{{se}} | {{se}} | ||
Side effects are uncommon, but may include headache, dizziness, fatigue, cough, gastrointestinal upset, and fetal toxicity. Several ARBs, but not specifically azilsartan, have been linked to a severe sprue-like enteropathy that typically arises after months or years of therapy and is unresponsive to gluten withdrawal, but resolves promptly with stopping the angiotensin receptor antagonist. | Side effects are uncommon, but may include headache, dizziness, fatigue, cough, gastrointestinal upset, and fetal toxicity. Several ARBs, but not specifically azilsartan, have been linked to a severe sprue-like enteropathy that typically arises after months or years of therapy and is unresponsive to gluten withdrawal, but resolves promptly with stopping the angiotensin receptor antagonist. | ||
{{htn}} | {{htn}} | ||
{{coststubd}} | {{coststubd}} | ||
{{Angiotensin receptor modulators}} | {{Angiotensin receptor modulators}} | ||
[[Category:Angiotensin II receptor antagonists]] | [[Category:Angiotensin II receptor antagonists]] | ||
Latest revision as of 08:14, 21 March 2025
Information about Azilsartan[edit]
Azilsartan is an angiotensin II receptor blocker (ARB) used in the therapy of hypertension.
Liver safety of Azilsartan[edit]
It is associated with a low rate of transient serum aminotransferase elevations, but has yet to be linked to instances of acute liver injury.
Mechanism of action of Azilsartan[edit]
Azilsartan (ay" sil sar' tan) is an ARB used alone or in combination with other agents for therapy of hypertension. Azilsartan inhibits the renin-angiotensin system by blocking the angiotensin II type 1 receptor (AT1), which prevents the vasoconstriction and volume expansion induced by circulating angiotensin II and which accounts for its antihypertensive activity.
FDA approval information for Azilsartan[edit]
Azilsartan was approved for use in the United States in 2011 (the eighth ARB approved for hypertension).
Current indications are for treatment of hypertension, either alone or in combination with other antihypertensive agents.
Dosage and administration for Azilsartan[edit]
Azilsartan is available in 40 and 80 mg tablets under the trade name Edarbi. Fixed combinations of azilsartan (40 mg) with chlorthalidone (12.5 or 25 mg) are also available under the brand name Edarbyclor. The typical dose in adults in 40 to 80 mg once daily, and it is used long term.
Side effects of Azilsartan[edit]
Side effects are uncommon, but may include headache, dizziness, fatigue, cough, gastrointestinal upset, and fetal toxicity. Several ARBs, but not specifically azilsartan, have been linked to a severe sprue-like enteropathy that typically arises after months or years of therapy and is unresponsive to gluten withdrawal, but resolves promptly with stopping the angiotensin receptor antagonist. Common ACE inhibitors include the following:
- Benazepril
- Captopril
- Enalapril
- Fosinopril
- Lisinopril
- Moexipril
- Perindopril
- Quinapril
- Ramipril
- Trandolapril
The common ARBS are the following:
